CLEAR III Intraventricular Thrombolysis Trial
Resolving IVH to improve outcomes
Home
Site Start-up
Study Documents
About Us
Contact Us
Participating Sites
Links

Welcome to the CLEAR III Home Page

 
CLEAR III is a Phase III randomized clinical trial (RCT) using recombinant tissue plasminogen activator (rtPA, Cathflo® Activase,® Genentech, Inc., San Francisco, CA) to treat subjects with intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), and hydrocephalus.


The primary aim of the study is to determine whether rapid removal of IVH clot with low-dose rtPA more likely improves modified Rankin Scores at 6 months (Rankin 0-3) compared to subjects treated with best medical care alone.

  Final Four Teleconferences          

     

To finalize the site initation process the Coordinating Center will be holding a teleconference with the key players at each site.  Click here for more info. 

  Pharmacist Training Sessions      


Updated dates and times for the CLEAR III Pharmacist Training sessions have been posted.  Click here to register for an upcoming session.  

 

The CLEAR III Trial is led by Study Chairman and co-Principal Investigator Dr. Daniel Hanley of

Johns Hopkins Medicine.  The study Surgical Center at NorthShore University HealthSystem (an affiliate of the University of Chicago Hospitals) is led by co-Principal Investigator Dr. Issam Awad.